Intermediate phenotypes in schizophrenia: A selective review

Dialogues in Clinical Neuroscience

Volumn 7, Issue 2, 2005, Pages 165-179

  Preston, Gilbert A ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Cognition; Electrophysiology; Genetics; Morphometry; Neuroimaging; Neuropsychology; Phenotype; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; RGS PROTEIN; RGS4 PROTEIN; UNCLASSIFIED DRUG;

ALLELE; BRAIN DEVELOPMENT; COGNITION; EVOKED CORTICAL RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GRM3 GENE; HERITABILITY; HUMAN; INFORMATION PROCESSING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POLYMORPHIC LOCUS; REVIEW; SCHIZOPHRENIA;

BRAIN; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE; SCHIZOPHRENIA;

EID: 21844450880     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Holzman PS, Kringlen E, Levy DL, Proctor LR, Haberman SJ, Yasillo NJ. Abnormal-pursuit eye movements in schizophrenia. Evidence for a genetic indicator. Arch Gen Psychiatry. 1977;34:802-805.
2. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636-645.
3. Coon H, Plaetke R, Holik J, et al. Use of a neurophysiological trait in linkage analysis of schizophrenia. Biol Psychiatry. 1993;34:277-289.
4. Egan MF, Duncan CC, Suddath RL, Kirch DG, Mirsky AF, Wyatt RJ. Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia. Schizophr Res. 1994;11:259-271.
5. Winterer G, Egan MF, Raedler T, et al. P300 and genetic risk for schizophrenia. Arch Gen Psychiatry. 2003;60:1158-1167.
6. Tsuang MT, Faraone SV, Lyons MJ. Identification of the phenotype in psychiatric genetics. Eur Arch Psychiatry Clin Neurosci. 1993;243:131-142.
7. van Beijsterveldt CEM, van Baal GCM. Twin and family studies of the human electroencephalogram: a review and meta-analysis. Biol Psychol. 2002;61:111-138.
8. Almasy L, Blangero J. Endophenotypes as quantitative risk factors for psychiatric disease: rationale and study design. Am J Med Genet. 2001;105:42-44.
9. Cornblatt BA, Malhotra AK. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am J Med Genet. 2001;105:11.
10. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40-68.
11. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122(Pt 4):593-624.
12. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl). 2004;174:151-162.
13. Harrison PJ, Weinberger DR. Schizophrenia genes within cortical neural circuits. Mol Psychiatry. 2005;10:1-4.
14. Egan MF, Goldberg TE. Intermediate cognitive phenotypes associated with schizophrenia. Methods Mol Med. 2003;77:163-197.
15. Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry. 2003;160:2209-2215.
16. Falconer DS, Mackay TFC, eds. Introduction to Quantitative Genetics. Vol 4. Harlow, UK: Longman; 1996.
17. Plomin R, DeFries JC, McClearn GE. Behavioral Genetics. 2nd ed. New York, NY: WH Freeman; 1990.
18. Goldberg TE, Torrey EF, Gold JM, et al. Genetic risk of neuropsychological impairment in schizophrenia: a study of monozygotic twins discordant and concordant for the disorder. Schizophr Res. 1995;17:77-84.
19. Cipollone F, Toniato E, Martinotti S, et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA. 2004;291:2221-2285.
20. Schwartz F, Duka A, Sun F, Cui J, Manolis A, Gavras H. Mitochondrial genome mutations in hypertensive individuals. Am J Hypertens. 2004;17:629-635.
21. Carlsson E, Groop L, Ridderstrale M. Role of the FOXC2 -512C>T polymorphism in type 2 diabetes: possible association with the dysmetabolic syndrome. Int J Obes Relat Metab Disord. 2005;29:268-274.
22. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia. 2004;47:2176-2184.
23. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med. 2004;350:2383-2397.
24. Baynes RD, Meyer TE, Bothwell TH, McNamara L. A screening test for detecting iron overload in population studies. S Afr Med J. 1988;74:167-169.
25. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood. 2003;101:3347-3350.
26. Tolosano E, Fagoonee S, Garuti C, et al. Haptoglobin modifies the hemochromatosis phenotype in mice. Blood. 2005;105:3353-3355.
27. McGurk SR, Mueser KT, Harvey PD, LaPuglia R, Marder J. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatr Serv. 2003;54:1129-1135.
28. McGurk SR, Moriarty PJ, Harvey PD, et al. Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. J Neuropsychiatry Clin Neurosci. 2000;12:257-264.
29. McGurk SR, Moriarty PJ, Harvey PD, Parrella M, White L, Davis KL. The longitudinal relationship of clinical symptoms, cognitive functioning, and adaptive life in geriatric schizophrenia. Schizophr Res. 2000;42:47-55.
30. Bryson G, Bell MD. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J Nerv Ment Dis. 2003;191:8-92.
31. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry. 2000;57:907-913.
32. Cannon TD, Huttunen MO, Lonnqvist J, et al. The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am J Hum Genet. 2000;67:369-382.
33. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci. 2004;8:325-335.
34. Egan MF. Relative risk of attention deficits in siblings of patients with schizophrenia. Am J Psychiatry. 2000;157:1309-1316.
35. Egan MF, Goldberg TE, Gscheidle T, et al. Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry. 2001;50:98-107.
36. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV. Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr Bull. 1994;20:103-119.
37. Finkelstein JR, Cannon TD, Gur RE, Gur RC, Moberg P. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J Abnorm Psychol. 1997;106:203-212.
38. Saoud M, d'Amato T, Gutknecht C, et al. Neuropsychological deficit in siblings discordant for schizophrenia. Schizophr Bull. 2000;26:893-902.
39. Chen WJ, Hsiao CK, Hsiao LL, Hwu HG. Performance of the continuous performance test among community samples. Schizophr Bull. 1998;24:1-74.
40. Strauss ME, Thompson P, Adams NL, Redline S, Burant C. Evaluation of a model of attention with confirmatory factor analysis. Neuropsychology. 2000;14:201-208.
41. Toomey R, Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Tsuang MT. Association of neuropsychological vulnerability markers in relatives of schizophrenic patients. Schizophr Res. 1998;31:89-98.
42. Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Lyons MJ, Tsuang MT. Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysis. J Abnorm Psychol. 1995;104:286-304.
43. Mirsky AF, Anthony BJ, Duncan CC, Ahearn MB, Kellam SG. Analysis of the elements of attention: a neuropsychological approach. Neuropsychol Rev. 1991;2:109-145.
44. Kremen WS, Tsuang MT, Faraone SV, Lyons MJ. Using vulnerability indicators to compare conceptual models of genetic heterogeneity in schizophrenia. J Nerv Ment Dis. 1992;180:141-152.
45. Keri S, Janka Z. Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand. 2004;110:83-91.
46. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2:924-926.
47. Weinberger DR, DeLisi LE, Neophytides AN, Wyatt RJ. Familial aspects of CT scan abnormalities in chronic schizophrenic patients. Psychiatry Res. 1981;4:65-71.
48. Reveley AM, Reveley MA, Clifford CA, Murray RM. Cerebral ventricular size in twins discordant for schizophrenia. Lancet. 1982;8271:540-541.
49. Hulshoff Pol HE, Brans RG, van Haren NE, et al. Gray and white matter volume abnormalities in monozygotic and same-gender dizygotic twins discordant for schizophrenia. Biol Psychiatry. 2004;55:126-130.
50. Gilmore JH, Perkins DO, Kliewer MA, et al. Fetal brain development of twins assessed in utero by ultrasound: implications for schizophrenia. Schizophr Res. 1996;19:141-149.
51. Tramo MJ, Loftus WC, Stukel TA, Green RL, Weaver JB, Gazzaniga MS. Brain size, head size, and intelligence quotient in monozygotic twins. Neurology. 1998;50:1246-1252.
52. Bertolino A, Nawroz S, Mattay VS, et al. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 1996;153:1554-1563.
53. Bertolino A, Esposito G, Callicott JH, et al. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry. 2000;157:26-33.
54. Callicott JH, Egan MF, Bertolino A, et al. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry. 1998;44:941-950.
55. Callicott JH. An expanded role for functional neuroimaging in schizophrenia. Curr Opin Neurobiol. 2003;13:256-260.
56. Callicott JH, Egan MF, Mattay VS, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia Am J Psychiatry. 2003;160:709-719.
57. Hofer A, Weiss EM, Golaszewski SM, et al. An FMRI study of episodic encoding and recognition of words in patients with schizophrenia in remission. Am J Psychiatry. 2003;160:911-918.
58. Ragland JD, Gur RC, Valdez J, et al. Event-related fMRI of frontotemporal activity during word encoding and recognition in schizophrenia. Am J Psychiatry. 2004;161:1004-1015.
59. Thermenos HW, Goldstein JM, Buka SL, et al. The effect of working memory performance on functional MRI in schizophrenia. Schizophr Res. 2005;74:179-194.
60. Adler LE PE, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry. 1982;17:639-654.
61. Siegel C, Waldo M, Mizner G, Adler LE, Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch Gen Psychiatry. 1984;41:607-612.
62. Freedman R, Adler LE, Gerhardt GA, et al. Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull. 1987;13:669-678.
63. Myles-Worsley M. P50 sensory gating in multiplex schizophrenia families from a Pacific island isolate. Am J Psychiatry. 2002;159:2007-2012.
64. Boutros NN, Belger A, Campbell D, D'Souza C, Krystal J. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Res. 1999;88:119-130.
65. Clementz BA, Blumenfeld LD. Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia. Exp Brain Res. 2001;139:377-390.
66. Myles-Worsley M, Coon H, Byerley W, Waldo M, Young D, Freedman R. Developmental and genetic influences on the P50 sensory gating phenotype. Biol Psychiatry. 1996;39:289-295.
67. Freedman R, Adams CE, Adler LE, et al. Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. Am J Med Genet. 2000;97:58-64.
68. Adler LE, Hoffer U, Griffith J, Waldo MC, Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 1992;32:607-616.
69. Myles-Worsley M, Ord L, Blailes F, Ngiralmau H, Freedman R. P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia. Biol Psychiatry. 2004;55:663-667.
70. 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry. 2002;59:1085-1096.
71. 7-like" nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. Mol Psychiatry. 2002;7:1006-1011.
72. Houy E, Raux G, Thibaut F, et al. The promoter -194 C polymorphism of the nicotinic α7 receptor gene has a protective effect against the P50 sensory gating deficit. Mol Pyschiatry. 2004;9:320-322.
73. Blackwood DH, Muir MW. Clinical phenotypes associated with DISC1, a candidate gene for schizophrenia. Neurotox Res. 2004;6:35-41.
74. Duncan CC, Perlstein WM, Morihisa JM. The P300 metric in schizophrenia: effects of probability and modality. Electroencephalogr Clin Neurophysiol Suppl. 1987;40:670-674.
75. Ford JM. Schizophrenia: the broken P300 and beyond. Psychophysiology. 1999;36:667-682.
76. Karoumi B, Laurent A, Rosenfeld F, et al. Alteration of event related potentials in siblings discordant for schizophrenia. Schizophr Res. 2000;41:325-334.
77. Winterer G, Egan MF, Radler T, Coppola R, Weinberger DR. Event-related potentials and genetic risk for schizophrenia. Biol Psychiatry. 2001;50:407-417.
78. Turetsky B, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia: II. Longitudinal stability and relationship to symptom change. Biol Psychiatry. 1998;43:31-39.
79. Turetsky Bl, Cannon TD, Gur RE. P300 subcomponent abnormalities in schizophrenia: III. Deficits in unaffected siblings of schizophrenic probands. Biol Psychiatry. 2000;47:380-390.
80. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004;27:683-690.
81. Harrison PJ, Eastwood SL. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus. 2001;11:508-519.
82. Lewis DA. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Brain Res Rev. 2000;31:270-276.
83. Honer WG. Presynaptic proteins and schizophrenia. In: Disorders of Synaptic Plasticity and Schizophrenia. Vol 59. Amsterdam, The Netherlands: Elsevier; 2004.
84. Mimics K, Middleton FA, Lewis DA, Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 2001;24:479-486.
85. Moises HW, Zoega T, Gottesman II. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry. 2002;2:8.
86. Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of schizophrenia. Neuron. 2003;39:205-216.
87. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003;73:34-48.
88. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;7:405-411.
89. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98:6917-6922.
90. Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 2003;60:889-896.
91. Ohnuma T, Tessler S, Arai H, Faull RL, McKenna PJ, Emson PC. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res. 2000;85:24-31.
92. Prasad KM, Chowdari KV, Nimgaonkar VL, Talkowski ME, Lewis DA, Keshavan MS. Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients. Mol Psychiatry. 2005;10:213-219.
93. Egan MF, Straub RE, Goldberg TE, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A. 2004;101:12604-12609.
94. Deakin JF, Slater P, Simpson MD, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem. 1989;52:1781-1786.
95. Akil M, Pierri JN, Whitehead RE, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry. 1999;156:1580-1589.
96. Albert KA, Hemmings HC, Jr, Adamo AI, et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry. 2002;59:705-712.
97. Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995;52:829-836.
98. Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem. 2000;75:889-907.
99. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit-based model of schizophrenia. Biol Psychiatry. 1999;45:17-25.
100. Gallinat J, Bajbouj M, Sander T, et al. Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry. 2003;54:40-48.
101. Chen X, Wang X, O'Neill AF, Walsh D, Kendler KS. Variants in the catechol-O-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry. 2004;9:962-967.
102. Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: metaanalysis of case-control and family-based studies. Am J Psychiatry. 2003;160:469-476.
103. de Chaldée M, Laurent C, Thibaut F, et al. Linkage disequilibrium on the COMT gene in French schizophrenics and controls. Am J Med Genet. 1999;88:452-457.
104. Aronica E, Gorter JA, Ijlst-Keizers H, et al. Expression and functional role of mGluR3 and mGluRS in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci. 2003;17:2106-2118.
105. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675-686.
106. Marti SB, Cichon S, Propping P, Nöthen M. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet. 2002;114:46-50.
107. Fujii Y, Shibata H, Kikuta R, et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2003;13:71-76.
108. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res. 1998;56:207-217.
109. Cartmell J, Monn JA, Schoepp DD. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl). 2000;148:423-429.
110. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349-1352.
111. Scherer SW, Duvoisin RM, Kuhn R, Heng HH, Belloni E, Tsui LC. Localization of two metabotropic glutamate receptor genes, GRM3 and GRM8, to human chromosome 7q. Genomics. 1996;31:230-233.
112. Quintana J, Wong T, Ortiz-Portillo E, et al. Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biol Psychiatry. 2003;53:12-24.
113. Chen Q, He G, Chen Q, et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res. 2005;73:21-26.
114. Chen ZY, Patel PD, Sant G, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci. 2004;24:4401-4411.
115. Lieberman JA, Jody D, Alvir JM, et al. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates. Arch Gen Psychiatry. 1993;50:357-368.
116. Kathmann N, Hochrein A, Uwer R, Bondy B. Deficits in gain of smooth pursuit eye movements in schizophrenia and affective disorder patients and their unaffected relatives. Am J Psychiatry. 2003;160:696-702.
117. Kathmann N, Engel RR. Sensory gating in normals and schizophrenics: a failure to find strong P50 suppression in normals. Biol Psychiatry. 1990;27:1216-1226.
118. Edgar JC, Huang MX, Weisend MP, et al. Interpreting abnormality: an EEG and MEG study of P50 and the auditory paired-stimulus paradigm. Biol Psychol. 2003;65:1-20.
119. Gevins A, Smith ME. Neurophysiological measures of working memory and individual differences in cognitive ability and cognitive style. Cereb Cortex. 2000;10:829-839.
120. Makeig S, Debener S, Onton J, Delorme A. Mining event-related brain dynamics. Trends Cogn Sci. 2004;8:204-210.
121. Kern RS, Green MF, Nuechterlein KH, Deng BH. NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. Schizophr Res. 2004;72:11-19.
122. Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry. 2004;65:361-372.
123. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301-307.
124. Hong LE, Summerfelt A, McMahon RP, Thaker GK, Buchanan RW. Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport. 2004;15:155-159.